Simmons & Simmons has advised Russian R-Pharm group on the acquisition of a production plant from Pfizer as well as a cooperation agreement.

The plant acquired by R-Pharm is located in the Bavarian town of Illertissen. The plant is producing Campix, a medication used to treat nicotine addiction which is now produced by R-Pharm for Pfizer.

R-Pharm group is a Russian life sciences company with 3,000 employees and an annual turnover of approximately US$2bn. With the acquisition of the Pfizer plant in Illertissen, R-Phram is taking further steps in its internationalisation strategy.

The team from Simmons & Simmons consisted of Corporate partners Boris Schilmar and Michael Bormann, Corporate counsel Vanessa Nieporte, Employment partner Verena Braeckeler-Kogel and Life Sciences regulatory specialist Associate Susanne Valluet.

Boris Schilmar and Vanessa Julia Nieporte joined Simmons & Simmons in early 2014 as part of the firm’s expansion of its Munich office, which opened last March. Their M&A and corporate focus play to the firm’s strengths in Germany and internationally. Boris’ partner status is subject to the usual regulatory approval.